Summit Therapeutics’ Upcoming Annual Shareholders’ Meeting
June 03 2021 - 7:00AM
Summit Therapeutics Inc. (NASDAQ: SMMT) invites our shareholders
and other interested parties to attend our Company’s Annual
Shareholders’ Meeting, which will be held virtually on Wednesday,
June 16, 2021, at 1:00 pm Eastern Time. We look forward to
your attendance at this meeting.
A link to the event can be found here:
www.virtualshareholdermeeting.com/SMMT2021.
About Summit TherapeuticsSummit Therapeutics,
empowered by its Discuva Platform, the Company’s innovative
antibiotic discovery engine, supported by BARDA and CARB-X funding,
intends to be the leader in patient-friendly and paradigm-shifting
treatments for infectious diseases and other significant unmet
medical needs while being an ally to physicians. Our new
mechanism pipeline product candidates are designed with the goal to
become the patient-friendly, new-era standard of care, by working
in harmony with the human microbiome to treat prospective patients
suffering from infectious disease, initially focusing on
Clostridioides difficile infections (CDI). The overriding
objective of Summit Therapeutics is to create value for patients,
hospital caregivers, and community-based healthcare providers, as
well as healthcare payers around the world. We seek to create
value by developing drugs with high therapeutic efficacy - curing
the cause of the patient's condition with minimal or zero disease
recurrence or antimicrobial resistance, for the longest extent
possible - and minimizing the trauma caused to the patient and
healthcare ecosystem by minimizing serious side effects, disease
recurrence, and inaccessibility to our treatments as a result of
financial or other barriers. Currently, Summit’s lead product
candidate, ridinilazole, is engaged in two pivotal global Phase 3
trials, Ri-CoDIFy 1 & 2, each enrolling approximately 680
patients vs. the standard of care (vancomycin) for the treatment
and reduction of recurrence of C. difficile infections, in addition
to an adolescent trial, Ri-CoDIFy 3. Commercialization of
ridinilazole for the treatment and the reduction of recurrence of
CDI is subject to regulatory approvals. SMT-738, the second
candidate within Summit’s portfolio, is currently in the
IND-enabling phase for the treatment of multidrug resistant
infections, specifically those caused by carbapenem-resistant
Enterobacteriaceae (CRE).
For more information, please visit www.summittxinc.com and
follow us on Twitter @summitplc. For more information on the
Company’s Discuva Platform, please visit
https://www.summittxinc.com/our-science/discuva-platform.
Contact Summit Investor
RelationsDave GancarzHead of Investor Relations &
Corporate Strategydavid.gancarz@summitplc.com
General Inquiries:
investors@summitplc.com
Summit Forward-looking
StatementsAny statements in this press release about the
Company’s future expectations, plans and prospects, including but
not limited to, statements about the clinical and preclinical
development of the Company’s product candidates, the therapeutic
potential of the Company’s product candidates, the potential
commercialization of the Company’s product candidates, the timing
of initiation, completion and availability of data from clinical
trials, the potential submission of applications for marketing
approvals, the impact of the COVID-19 pandemic on the Company’s
operations and clinical trials and other statements containing the
words "anticipate," "believe," "continue," "could," "estimate,"
"expect," "intend," "may," "plan," "potential," "predict,"
"project," "should," "target," "would," and similar expressions,
constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by such forward-looking
statements as a result of various important factors, including: the
uncertainties inherent in the initiation of future clinical trials,
availability and timing of data from ongoing and future clinical
trials and the results of such trials, global public health crises,
including the coronavirus COVID-19 outbreak, that may affect timing
and status of our clinical trials and operations, whether
preliminary results from a clinical trial will be predictive of the
final results of that trial or whether results of early clinical
trials or preclinical studies will be indicative of the results of
later clinical trials, expectations for regulatory approvals, laws
and regulations affecting government contracts and funding awards,
availability of funding sufficient for the Company’s foreseeable
and unforeseeable operating expenses and capital expenditure
requirements and other factors discussed in the "Risk Factors"
section of filings that the Company makes with the Securities and
Exchange Commission. Accordingly, readers should not place undue
reliance on forward-looking statements or information. In addition,
any forward-looking statements included in this press release
represent the Company’s views only as of the date of this release
and should not be relied upon as representing the Company’s views
as of any subsequent date. The Company specifically disclaims any
obligation to update any forward-looking statements included in
this press release.
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jul 2023 to Jul 2024